Novartis ranked #4 in Fortune’s list of companies that are doing well by doing good. The list recognizes companies that have a positive social impact through activities that are part of their core business strategy.
Novartis included in Dow Jones Sustainability World Index 2017
Novartis was ranked fourth in the 2017 Dow Jones Sustainability Index (DJSI) World (up from 7th in 2016), and re-entered the DJSI Europe Index for the first time in four years. The DJSI assessment has become the gold-standard for assessing the ESG (environmental, social and governance) performance of companies worldwide.
Novartis on FORTUNE's list of the World's Most Admired Companies 2017
Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list. This is the third consecutive year that Novartis ranked as the second-most-admired company in our sector, and the 13th consecutive year that Novartis is in the top three.
Novartis among 2017 Global 100 Most Sustainable Corporations list by Corporate Knights
The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using up to 14 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.
PatientView 2016 ranks Novartis in top 3 companies with best reputation among patient groups
On March 21, 2017, PatientView released their "Corporate Reputation of Pharma in 2016; The Patient Perspective." Novartis is honored to be amongst the top 3 companies with the best corporate reputation among patient groups in 2016. Novartis is also proud to be recognized as the number one partner for patient groups, having worked with 395 groups in the past five years. Novartis places second in "corporate brand awareness" amongst patient groups. PatientView's results are based on a survey among 1,463 patient groups from 105 countries.
Novartis is featured as one of the 2016 “Top 100 Global Innovators”
Novartis is featured as one of the 2016 “Top 100 Global Innovators,” as compiled by Clarivate Analytics (formerly the “IP & Science” division of Thomson Reuters). Novartis is listed for the third consecutive time.
Novartis ranks third in 2016 Access to Medicine Index
Novartis ranked third in the 2016 Access to Medicine Index, up from 4th place in 2014. We topped the industry in access-to-medicine management and capacity building, and our integrated access strategy addressing all income segments stood out as best practice.
Two Novartis products receive 2016 Prix Galien Foundation Awards
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate).
Novartis has been ranked among the top green companies in the world by 2016 Newsweek Green Rankings. Since 2009, the Newsweek Green Rankings, created in partnership with Corporate Knights and HIP Investor, have been one of the world’s foremost corporate environmental rankings which assess the 500 largest publicly-traded companies in the United States and the 500 largest publicly-traded companies globally on overall environmental performance.